(secondQuint)Docetaxel in Treating Patients With Solid Tumors.

 OBJECTIVES: - Compare the population pharmacokinetics of docetaxel in Caucasians and African American patients with solid tumors.

 - Compare the pharmacodynamic effect of a single dose of docetaxel in relation to hematological toxicity in these patient populations.

 - Determine the CYP3A4 genotype and P-glycoprotein (P-gp) expression and their relationship to docetaxel clearance in these patient populations.

 OUTLINE: Patients receive docetaxel IV over 1 hour on day 1.

 Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.

.

 Docetaxel in Treating Patients With Solid Tumors@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.

